Prognostic value of microRNAs in cervical carcinoma: a systematic review and meta-analysis

作者：Shengkang Dai, Yan Lü, Ying Long, Yuehua Lai, Ping Du, Nan Ding, Desheng Yao · 发表于：Oncotarget · 年份：2016 · DOI：10.18632/oncotarget.9294 · 被引用次数：23 · 研究领域：Circular RNAs in diseases、MicroRNA in disease regulation、Endometrial and Cervical Cancer Treatments

// Shengkang Dai 1 , Yan Lu 1 , Ying Long 1 , Yuehua Lai 1 , Ping Du 1 , Nan Ding 1 , Desheng Yao 1 1 Department of Gynecologic Oncology, The Affiliated Tumor Hospital of Guangxi Medical University, Nanning, Guangxi, China Correspondence to: Desheng Yao, e-mail: yaodeson@163.com Keywords: microRNA, prognosis, cervical carcinoma, meta-analysis Received: December 08, 2015     Accepted: April 11, 2016     Published: May 11, 2016 ABSTRACT This systematic review is written to investigate the outcome of cervical cancer. A comprehensive search of PubMed and EMBASE was performed to identify eligible studies. Nineteen studies from thirteen articles with a total of 1,310 participants were included in this meta-analysis. Overall survival (OS), disease-free survival (DFS), and recurrence-free survival (RFS) as a prognosis for cervical cancer were extracted and calculated, if available. Pooled hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated using STATA (version 12.0), resulting in the pooled HRs 0.70 (95% CI: 0.51–0.97) for OS, 1.02 (95% CI: 0.53–1.98) for DFS, and 0.56 (95% CI: 0.40–0.77) for RFS. The results indicated that cervical cancer patients with decreased microRNA expression were associated with shorter OS and RFS. It suggested that microRNAs might be promising markers for predicting the survival rate of cervical cancer.